Syntara Limited has released a press release.
Acceleration of skin scarring program
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Syntara
- Placement
- Equity Raising Presentation
- Interim data in Phase 2 study of SNT-5505 in myelofibrosis
- Presentation: Phase 2 study of SNT-5505 in myelofibrosis
- Trading Halt
Later from Syntara
- Quarterly Activities Report
- SNT-5505 awarded US FDA Fast Track designation
- New positive interim data in Phase 2 study of SNT-5505
- Quarterly Shareholder Report
- Quarterly Appendix 4C Cash Flow Report
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara